Evidence-based recommendations on conventional systemic treatments in psoriasis: Systematic review and expert opinion of a panel of dermatologists

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue SUPPL. 2, 2011, Pages 2-11

  Paul, C ^a   Gallini, A ^b   Maza, A ^a   Montaudie H ^c   Sbidian, E ^d   Aractingi, S ^e   Aubin, F ^f   Bachelez, H ^d   Cribier, B ^g   Joly, P ^h   Jullien, D ⁱ   Le Maitre M ^j   Misery, L ^k   Richard, M A ^l   Ortonne, J P ^c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSERM   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g Dermatology Department   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j Timone Hospital ^*

^k BREST UNIVERSITY HOSPITAL   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETIN; ETRETINATE; FOLIC ACID; FOLINIC ACID; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RETINOID; STEROID; VITAMIN D DERIVATIVE;

ARTHROPATHY; BONE DISEASE; BONE TOXICITY; CLINICAL PRACTICE; CLINICAL PROTOCOL; COCHRANE LIBRARY; CONSENSUS; DERMATOLOGIST; DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EMBASE; EVIDENCE BASED PRACTICE; GASTROINTESTINAL TOXICITY; HUMAN; HYPEROSTOSIS; JOINT TOXICITY; LIVER FIBROSIS; LIVER TOXICITY; MEDICAL SPECIALIST; MEDLINE; META ANALYSIS; MONOTHERAPY; NEPHROTOXICITY; PATIENT MONITORING; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PUSTULAR PSORIASIS; PUVA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EID: 79952567376     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.03990.x     Document Type: Review

References (74)

1. Strowd LC, Yentzer BA, Fleischer AB Jr et al. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol 2009; 60: 478-481.
2. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity : effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-182.
3. Fredrikkson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
4. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555. (Pubitemid 9258270)
5. Roenigk HH, Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-485. (Pubitemid 28125534)
6. Griffiths CEM, Dubertret L, Ellis CN et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004; 150: 11-23. (Pubitemid 38903574)
7. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
8. Montaudié H, Sbidian E, Paul C et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25(Suppl. 2): 12-18.
9. Maza A, Montaudié H, Sbidian E et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non plaque psoriasis. J Eur Acad Dermatol Venereol 2011; 25(Suppl. 2): 19-27.
10. Sbidian E, Maza A, Montaudié H et al. Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. J Eur Acad Dermatol Venereol 2011; 25(Suppl. 2): 28-33.
11. van Tulder M, Furlan A, Bombardier C et al. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 2003; 28: 1290-1299. (Pubitemid 36734620)
12. Sackett DL, Richardson WS, Rosenberg WM et al. Evidence-Based Medicine: How to Practice and Teach EBM. Churchill Livingstone, London (UK), 1997.
13. Roddy E, Zhang W, Doherty M et al. Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J Eval Clin Pract 2006; 12: 347-352. (Pubitemid 43806715)
14. Chládek J, Simková M, Vanecková J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347-355.
15. Salim A, Tan E, Ilchyshyn A et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154: 1169-1174. (Pubitemid 43727401)
16. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-1524. (Pubitemid 32651731)
17. Malatjalian DA, Ross JB, Williams CN et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10: 369-375. (Pubitemid 26364819)
18. Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118. (Pubitemid 46669734)
19. Themido R, Loureiro M, Pecegueiro M et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992; 72: 361-364.
20. Boffa MJ, Smith A, Chalmers RJ et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermato 1996; 135: 538-544. (Pubitemid 26341933)
21. Mitchell D, Smith A, Rowan B et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990; 122: 1-7. (Pubitemid 20047028)
22. Zachariae H, Søgaard H, Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venereol 1989; 69: 241-244.
23. Zachariae H, Aslam HM, Bjerring P et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25(1 Pt 1): 50-53.
24. Berends MA, Snoek J, de Jong EM et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27: 639-645. (Pubitemid 47097314)
25. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. New Engl J Med 1991; 324: 277-284.
26. IMSGP - Italian Multicenter Study Group on Cyclosporin in Psoriasis. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Dermatology 1993; 187(suppl 1): 8-18.
27. Laburte C, Grossman R, Abi-Rached J et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366-375. (Pubitemid 24204648)
28. Mahrle G, Schulze HJ, Färber L et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88.
29. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998; 139: 88-95. (Pubitemid 28338069)
30. Ohtsuki M, Nakagawa H, Sugai J et al. Long-term continuous versus intermittent cyclosporine: therapy for psoriasis. J Dermatol 2003; 30: 290-298. (Pubitemid 36554137)
31. Chaidemenos GC, Mourellou O, Avgoustinaki N et al. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 1203-1208. (Pubitemid 47423408)
32. Gisondi P, Del Giglio M, Di Francesco V et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
33. Lowe NJ, Wieder JM, Rosenbach A et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710-719. (Pubitemid 26389470)
34. Young EW, Ellis CN, Messana JM et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1994; 46: 1216-1222. (Pubitemid 24319964)
35. Thaçi D, Bräutigam M, Kaufmann R et al. Bodyweight- independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 2002; 205: 383-388. (Pubitemid 35356767)
36. Korstanje MJ, Bilo HJ, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br J Dermatol 1992; 127: 501-504.
37. Reitamo S, Erkko P, Remitz A et al. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo controlled study. Arch Dermatol 1993; 129: 1273-1279.
38. Erkko P, Granlund H, Remitz A et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1998; 139: 997-1004. (Pubitemid 29010536)
39. SIMPSO - Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano multicentrico nella psoriasi (SIMPSO). Dermatology 1993; 187: 30-37.
40. Feliciani C, Zampetti A, Forleo P et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 2004;8:122-125. Epub 2004 May 3. (Pubitemid 38781366)
41. Murray HE, Anhalt AW, Lessard R et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991; 24: 598-602.
42. Olsen EA, Weed WW, Meyer CJ et al. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-686. (Pubitemid 19251725)
43. Finzi AF, Mozzanica N, Pigatto PD et al. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Dermatology 1993; 187: 8-18. (Pubitemid 23223843)
44. Kragballe K, Jansen CT, Geiger J-M et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis: Results of a Nordic multicentre study. Acta Derm Venereol 1989; 69: 35-40. (Pubitemid 19028329)
45. Ledo A, Martin M, Geiger JM et al. Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate. Int J Dermat 1988; 27: 656-660. (Pubitemid 19000381)
46. Gollnick H, Bauer R, Brindley C et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988; 3: 458-468.
47. Berbis P, Geiger J-M, Vaisse C et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989; 178: 88-92. (Pubitemid 19058799)
48. Goldfarb MT, Ellis CN, Gupta AK et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988; 18: 655-662.
49. Kullavanijaya P, Kulthanan K. Clinical efficacy and side effects of acitretin on the disorders of keratinisation: a one-year study. J Dermatol 1993; 20: 501-506. (Pubitemid 23274612)
50. Hohl D, Pelloni F, Sigg C et al. A prospective study of skeletal changes during short-term acitretin therapy. Dermatology 1992; 185: 23-26.
51. Kilcoyne RF. Acitretin effects on the spine. Dermatologica 1990; 181: 359-360.
52. Gilbert M, Ellis CN, Voorhees JJ. Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis. Dermatologica 1986; 172: 160-163. (Pubitemid 16167304)
53. Van Dooren-Greebe RJ, Lemmens JA, De Boo T et al. Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 1996; 134: 71-76. (Pubitemid 26030996)
54. Mørk NJ, Kolbenstvedt A, Austad J. Skeletal side-effects of 5 years' acitretin treatment. Br J Dermatol 1996; 134: 1156-1157. (Pubitemid 26183159)
55. Vestergaard P, Rejnmark L, Mosekilde L. High-dose treatment with vitamin a analogues and risk of fractures. Arch Dermatol 2010; 146: 478-482.
56. Foged E, Holm P, Larsen PO. A randomized trial of etretinate (Tigason) in palmoplantar pustulosis. Dermatologica 1983; 166: 220-223. (Pubitemid 13119958)
57. White SI, Puttick L, Marks JM. Low-dose etretinate in the maintenance of remission of palmoplantar pustular psoriasis. Br J Dermatol 1986; 115: 577-582. (Pubitemid 16009012)
58. Fredriksson T, Pettersson U. Oral treatment of pustulosis palmoplantaris with a new retinoid, Ro 10-9359. Dermatologica 1979; 158: 60-64. (Pubitemid 9084747)
59. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988; 119: 755-759. (Pubitemid 19002627)
60. Thune P. Treatment of palmoplantar pustulosis with Tigason. Dermatologic 1982; 164: 167-172.
61. Rosen K, Mobacken H, Swanbeck G. Puva, etretinate, and puva-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial. Arch Dermatol 1987; 123: 885-889.
62. Lawrence CM, Marks J, Parker S, Shuster S. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol 1984; 110: 221-226. (Pubitemid 14184214)
63. Matsunami E, Takashima A, Mizuno N, Jinno T, Ito H. Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. J Dermatol 1990; 17: 92-96. (Pubitemid 20191472)
64. Ettler K, Richards B. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol 2001; 40: 541-542. (Pubitemid 33026318)
65. Lassus A, Lauharanta J, Eskelinen A. The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis. Br J Dermatol 1985; 112: 455-459. (Pubitemid 15148491)
66. Tosti A, Ricotti C, Romanelli P et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. BM Arch Dermatol 2009; 145: 269-271.
67. Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol 2001; 144: 1000-1005.
68. Wolska H, Jablonska S, Langner A, Fraczykowska M. Etretinate therapy in generalized pustular psoriasis (Zumbusch type). Immediate and long-term results. Dermatologica 1985; 171: 297-304. (Pubitemid 16200738)
69. Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. British Med J 2003; 326: 41-44. (Pubitemid 36110721)
70. Spuls PI, Nast A. Evaluation of and perspectives on guidelines: what is important? J Invest Dermatol 2010; 130: 2348-2349.
71. Alvarez F, Meyer N, Gourraud PA, Paul C. CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. Br J Dermatol, 2009;161:1159-1165. Epub 2009 Jun 6
72. Djulbegovic B, Trikalinos TA, Roback J et al. Impact of quality of evidence on the strength of recommendations: an empirical study. BMC Health services research 2009; 9: 120.
73. Bernard P, Christmann D, Morel M. Management of erysipelas in French hospitals: a post-consensus conference study. Ann Dermatol Venereol 2005; 132: 213-217. (Pubitemid 40546486)
74. Akl EA, Mustafa R, Wilson MC et al. Curricula for teaching the content of clinical practice guidelines to family medicine and internal medicine residents in the US: a survey study. Implement Sci 2009; 4: 59.